Umbilical cord blood mononuclear cell therapy induces clinical remission of steroid-dependent or -resistant ulcerative colitis patients
Metrics: PDF 1058 views | HTML 1773 views | ?
Liang Chen1,3, Yuan Gao3, Zongmei Zhang3, Mingming Sun1, Wenjing Yang1, Zhanju Liu1 and Xueliang Jiang2,3
1Department of Gastroenterology, The Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
2Department of Digestive Center, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
3Department of Gastroenterology, Chinese PLA General Hospital of Jinan Military Command, Jinan, China
Xueliang Jiang, email: email@example.com
Zhanju Liu, email: firstname.lastname@example.org
Keywords: umbilical cord blood mononuclear cells; azathioprine; steroid-dependent or -resistant ulcerative colitis; clinical remission
Received: July 27, 2017 Accepted: November 16, 2017 Epub: January 04, 2018 Published: March 13, 2018
To compare the efficacy and safety of umbilical cord blood mononuclear cells (CBMNC) and azathioprine (AZA) in the treatment of patients with steroid-dependent or -resistant ulcerative colitis. One hundred and six patients diagnosed with steroid-dependent or -resistant ulcerative colitis were studied retrospectively, including 36 patients treated with CBMNC and 70 treated with AZA. To reduce confounding bias due to retrospective nature of this study, the propensity score matching system was applied to equipoise the pretreatment data of two groups. After matching, 35 matched pairs (1:1) were created. The ratios of clinical remission, clinical response and endoscopic mucosal healing, Mayo score, and major complications were compared between two groups at weeks 8, 16, and 36 after treatment. The results demonstrated that the ratios of clinical remission (80% vs.57%, P < 0.05) and mucosal healing (74% vs. 51%, P < 0.05) were significantly higher in CBMNC-treated patients compared with those in AZA-treated patients at week 8. The erythrocyte sedimentation rate was significantly decreased in CBMNC group compared with that in AZA-treated group (14.5 ± 3.9 mm/h vs. 18.0 ± 5.7 mm/h, P < 0.01) at week 8. In AZA group, 2 patients had neutropenia and 3 patients had elevated alanine aminotransferase levels, whereas no obvious side-effects were observed in CBMNC-treated group. Our results reveal that CBMNC therapy appears to be an effective and safe strategy for patients with steroid-dependent or -resistant ulcerative colitis. Further prospective studies are needed to define the potential roles and mechanisms of CBMNC in the treatment of refractory ulcerative colitis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.